Zucara Therapeutics

Zucara Therapeutics is developing ZT-01, a first-in-class therapeutic designed to prevent insulin-induced hypoglycemia in patients treated with insulin. ZT-01 aims to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in individuals with insulin-dependent diabetes. By restoring glucagon secretion to prevent hypoglycemia, ZT-01 has the potential to significantly transform diabetes management and improve patient health and quality of life.